NEW YORK, NY / ACCESSWIRE / April 6, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Investors Affected : May 28, 2021 - November 26, 2021
A class action has commenced on behalf of certain shareholders in Fennec Pharmaceuticals Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/fennec-pharmaceuticals-inc-loss-submission-form-2/?id=25642&from=1
Affirm Holdings, Inc. (NASDAQ:AFRM)
This lawsuit is on behalf of all investors who purchased or otherwise acquired Affirm Holdings, Inc. securities on February 10, 2022 after the Company sent a Tweet concerning its Second Quarter 2022 financial results at approximately 1:15 p.m. EST.
A class action has commenced on behalf of certain shareholders in Affirm Holdings, Inc. (i) Affirm's "buy now, pay-later" service facilitated excessive consumer debt, regulatory arbitrage, and data harvesting; (ii) the foregoing subjected Affirm to a heightened risk of regulatory scrutiny and enforcement action; (iii) Affirm maintained inadequate disclosure controls and procedures and internal control over financial reporting; (iv) accordingly, Affirm's tweet for its second quarter 2022 financial results contained selected metrics that made it appear that the Company had performed better than it actually did; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/affirm-holdings-inc-loss-submission-form/?id=25642&from=1
Everbridge, Inc. (NASDAQ:EVBG)
Investors Affected : November 4, 2019 - February 24, 2022
A class action has commenced on behalf of certain shareholders in Everbridge, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Everbridge was experiencing integration problems with respect to several of its recent acquisitions; (2) the Company was using the revenues from these acquisitions to mask increasingly stagnant organic growth; and (3) the COVID pandemic was having a material impact on the size of the deals that Everbridge was able to obtain, negatively affecting the Company's revenue growth.
Shareholders may find more information at https://securitiesclasslaw.com/securities/everbridge-inc-loss-submission-form/?id=25642&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm